[go: up one dir, main page]

CA2503715A1 - Inhibiteurs de kinase - Google Patents

Inhibiteurs de kinase Download PDF

Info

Publication number
CA2503715A1
CA2503715A1 CA002503715A CA2503715A CA2503715A1 CA 2503715 A1 CA2503715 A1 CA 2503715A1 CA 002503715 A CA002503715 A CA 002503715A CA 2503715 A CA2503715 A CA 2503715A CA 2503715 A1 CA2503715 A1 CA 2503715A1
Authority
CA
Canada
Prior art keywords
amino
compound
carbonitrile
thiazole
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002503715A
Other languages
English (en)
Inventor
George D. Hartman
Jacob M. Hoffman
Anthony M. Smith
Thomas J. Tucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2503715A1 publication Critical patent/CA2503715A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés qui inhibent, régulent et/ou modulent la traduction du signal de la kinase, des compositions contenant ces composés et, des techniques d'utilisation de ces compositions pour traiter des maladies et des pathologies dépendant de la kinase, telles que l'angiogenèse, le cancer, la croissance tumorale, l'athérosclérose, la dégénération maculaire liée à l'âge, l'ischémie rétinienne, l'oedème maculaire, la rétinopathie diabétique, des maladies inflammatoires et d'autres maladies similaires chez les mammifères.
CA002503715A 2002-10-30 2003-10-24 Inhibiteurs de kinase Abandoned CA2503715A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42231302P 2002-10-30 2002-10-30
US60/422,313 2002-10-30
PCT/US2003/034100 WO2004041164A2 (fr) 2002-10-30 2003-10-24 Inhibiteurs de kinase

Publications (1)

Publication Number Publication Date
CA2503715A1 true CA2503715A1 (fr) 2004-05-21

Family

ID=32312490

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002503715A Abandoned CA2503715A1 (fr) 2002-10-30 2003-10-24 Inhibiteurs de kinase

Country Status (5)

Country Link
EP (1) EP1558609A4 (fr)
JP (1) JP2006507302A (fr)
AU (1) AU2003285007A1 (fr)
CA (1) CA2503715A1 (fr)
WO (1) WO2004041164A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004009295T2 (de) 2003-01-14 2008-07-03 Arena Pharmaceuticals, Inc., San Diego 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
US8168568B1 (en) 2003-03-10 2012-05-01 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Combinatorial therapy for protein signaling diseases
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
ATE415397T1 (de) * 2004-06-04 2008-12-15 Arena Pharm Inc Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
AU2005314133B2 (en) 2004-12-06 2012-03-08 Medicinova, Inc. Ibudilast for treating neuropathic pain and associated syndromes
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
ES2349657T3 (es) 2005-04-29 2011-01-10 Ferring International Center S.A. Tratamiento o prevención del síndrome de hiperestimulación ovárica (sho) usando un agonista de domamina.
US20090221581A1 (en) * 2005-05-25 2009-09-03 Philipp Wabnitz Methods of treating pain
EP1968596A4 (fr) * 2005-12-22 2010-12-01 Icagen Inc Antagonistes du canal calcique
JP5236499B2 (ja) * 2006-01-27 2013-07-17 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
WO2008129380A1 (fr) 2007-04-18 2008-10-30 Pfizer Products Inc. Dérivés de sulfonyle amide pour le traitement d'une croissance cellulaire anormale
EP2137166B1 (fr) 2007-04-24 2012-05-30 Ingenium Pharmaceuticals GmbH Dérivés d'aminopyrimidines 4,6 disubstitués comme inhibiteurs de protéine kinase
EP3078662A1 (fr) 2007-09-21 2016-10-12 Array Biopharma, Inc. Dérivés pyridin-2-yl-amino-1,2,4-thiadiazole en tant qu'activateurs de la glucokinase pour le traitement de la diabète sucré
GB0811955D0 (en) 2008-06-30 2008-07-30 Pci Biotech As Method
US20100113479A1 (en) * 2008-10-30 2010-05-06 Anusuya Choudhury Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists
JP5607241B2 (ja) 2010-05-21 2014-10-15 ケミリア・エービー 新規ピリミジン誘導体
PH12013500547A1 (en) 2010-09-22 2013-06-10 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2688883B1 (fr) 2011-03-24 2016-05-18 Noviga Research AB Dérivés de pyrimidine
EP2702043A1 (fr) * 2011-04-29 2014-03-05 Exelixis, Inc. Inhibiteurs de la forme inductible de la 6-phosphofructose-2-kinase
ES2995737T3 (en) 2015-01-06 2025-02-11 Arena Pharm Inc Compound for use in treating conditions related to the s1p1 receptor
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
TWI620748B (zh) * 2016-02-05 2018-04-11 National Health Research Institutes 氨基噻唑化合物及其用途
RS66574B1 (sr) 2016-07-29 2025-03-31 Janssen Pharmaceutica Nv Niraparib za upotrebu u postupku lečenja raka prostate
WO2018151873A1 (fr) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Composés et méthodes de traitement de l'angiocholite biliaire primitive
TWI667236B (zh) * 2017-06-13 2019-08-01 財團法人國家衛生研究院 作為蛋白激酶抑制劑的胺基噻唑化合物
EP3801459B1 (fr) 2018-06-06 2024-08-07 Arena Pharmaceuticals, Inc. Méthodes de traitement de troubles associés au récepteur s1p1
DK3643713T3 (da) * 2018-10-23 2025-11-03 Iomx Therapeutics Ag Heterocykliske kinaseinhibitorer og deres anvendelse
CN111116575B (zh) * 2019-12-18 2021-06-15 浙江工业大学 一种5-氟-2,4-嘧啶二胺类化合物及其制备与应用
CN111388656B (zh) * 2020-04-17 2021-01-15 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Kallistatin蛋白在制备防治OHSS的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1348370A (zh) * 1999-04-15 2002-05-08 布里斯托尔-迈尔斯斯奎布公司 环状蛋白酪氨酸激酶抑制剂
US20020137755A1 (en) * 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
DK1347971T3 (da) * 2000-12-21 2006-05-15 Bristol Myers Squibb Co Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien

Also Published As

Publication number Publication date
WO2004041164A2 (fr) 2004-05-21
EP1558609A2 (fr) 2005-08-03
WO2004041164A3 (fr) 2004-10-07
JP2006507302A (ja) 2006-03-02
EP1558609A4 (fr) 2008-05-28
AU2003285007A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
US7115597B2 (en) Tyrosine kinase inhibitors
EP1503757B1 (fr) Inhibiteurs de la tyrosine kinase
CA2503715A1 (fr) Inhibiteurs de kinase
US6958340B2 (en) Tyrosine kinase inhibitors
EP1259235B1 (fr) Inhibiteurs de tyrosine kinase
EP1218376B1 (fr) Inhibiteurs de tyrosine kinase
EP1226119B1 (fr) Inhibiteurs tyrosine kinase
US6927293B2 (en) Tyrosine kinase inhibitors
EP1226136B1 (fr) Inhibiteurs de tyrosine kinases
US7265134B2 (en) Tyrosine kinase inhibitors
US20040171630A1 (en) Tyrosine kinase inhibitors
US20050070546A1 (en) Tyrosine kinase inhibitors
US20040235875A1 (en) Tyrosine kinase inhibitors
US20040220216A1 (en) Tyrosine kinase inhibitors
WO2003024931A1 (fr) Inhibiteurs de tyrosine kinase
WO2001062252A1 (fr) Inhibiteurs de tyrosine-kinase
WO2003011838A1 (fr) Inhibiteurs de la tyrosine kinase

Legal Events

Date Code Title Description
FZDE Dead